Literature DB >> 12695526

Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.

Jilin Liu1, Hui Li, Sumner H Burstein, Robert B Zurier, J Don Chen.   

Abstract

Ajulemic acid (AJA) is a synthetic analog of the tetrahydrocannabinol (THC) metabolite THC-11-oic acid; THC is a major active ingredient of the drug marijuana derived from the plant cannabis. AJA has potent analgesic and anti-inflammatory activity without the psychotropic action of THC. Unlike the nonsteroidal anti-inflammatory drugs, AJA is not ulcerogenic at therapeutic doses, making it a promising anti-inflammatory drug. However, the mechanism of AJA action remains unknown. Here we report that AJA binds directly and specifically to the peroxisome proliferator-activated receptor gamma (PPARgamma), a pharmacologically important member of the nuclear receptor superfamily. Functional assay indicates that AJA activates the transcriptional activity of both human and mouse PPARgamma at pharmacological concentrations. Activation of PPARgamma by AJA requires the AF-2 helix of the receptor, suggesting that AJA activates PPARgamma through the ligand-dependent AF-2 function. AJA binding consistently enables PPARgamma to recruit nuclear receptor coactivators. In addition, we show that AJA inhibits interleukin-8 promoter activity in a PPARgamma-dependent manner, suggesting a link between the anti-inflammatory action of AJA and the activation of PPARgamma. Finally, we find that AJA treatment induces differentiation of 3T3 L1 fibroblasts into adipocytes, a process mediated by PPARgamma. Together, these data indicate that PPARgamma may be a molecular target for AJA, providing a potential mechanism for the anti-inflammatory action of AJA, and possibly other cannabinoids. These studies also implicate other potential therapeutic actions of AJA through PPARgamma activation in multiple signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695526     DOI: 10.1124/mol.63.5.983

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  38 in total

Review 1.  Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.

Authors:  D Cota; S Genghini; R Pasquali; U Pagotto
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

Review 2.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

5.  A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.

Authors:  Aitor G Granja; Francisco Carrillo-Salinas; Alberto Pagani; María Gómez-Cañas; Roberto Negri; Carmen Navarrete; Miriam Mecha; Leyre Mestre; Bend L Fiebich; Irene Cantarero; Marco A Calzado; Maria L Bellido; Javier Fernandez-Ruiz; Giovanni Appendino; Carmen Guaza; Eduardo Muñoz
Journal:  J Neuroimmune Pharmacol       Date:  2012-09-14       Impact factor: 4.147

Review 6.  Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.

Authors:  Summer Burstein
Journal:  AAPS J       Date:  2005-06-29       Impact factor: 4.009

Review 7.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

8.  Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

Authors:  Sean D McAllister; Calvin Chan; Ryan J Taft; Tri Luu; Mary E Abood; Dan H Moore; Ken Aldape; Garret Yount
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 9.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 10.  Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

Authors:  Elizabeth J Rahn; Andrea G Hohmann
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.